The figures, for anyone assembling their own picture. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Following on from Dr.RheumBOS — and this may be the naive question:
What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?
PharmacoVig_BOS said:Worth knowing that the injection site changes very little.
Maintenance phase reality on maintenance dosing: reached my goal 5 months ago and now I'm in maintenance. It's a different mental game.
During weight loss, the scale going down is constant positive reinforcement. In maintenance, the scale staying the same is... just... nothing. It's anticlimactic. The dopamine hit is gone.
What keeps me going: lab improvements, physical capabilities, how I feel, fitting in clothes I love, and the knowledge that regain happens when people stop being intentional. I'm staying intentional.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsPharmacoVig_BOS said:Worth knowing that the injection site changes very little.
The concept of "metabolic set point" and its relevance to maintenance dosing: the body actively defends a weight set point through hormonal feedback (leptin, ghrelin, insulin, GLP-1). After weight loss, these signals shift to promote weight regain[1].
GLP-1 agonists may work in part by resetting this set point — or at least overriding the counter-regulatory signals that drive regain. This would explain why continued treatment maintains weight loss while discontinuation leads to regain.
Understanding maintenance dosing through this lens reframes the drug from "weight loss tool" to "metabolic set point modulator."
[1] Rosenbaum M, et al. J Clin Invest. 2008;118(7):2583-2591.
PharmacoVig_BOS said:Worth knowing that the injection site changes very little.
Bookmarking. The distinction being drawn above is the one nobody else makes. I will report back once I have actually tried it.